The Extent to Which the HPV Vaccine Reduces Cervical Cancer Risk Has Been Determined

In a study published on 1 October in NEJM, quadrivalent human papillomavirus (HPV) vaccination helped women in different age groups vaccinated between 2006-2017 have their cervical cancer risk substantially reduced . The importance of age at vaccination, the possibility that the 4-valent vaccine may not protect against all HPV types, and lifestyle were also emphasized.
Although the quadrivalent HPV vaccine sold under the trade name Gardasil had been shown to help prevent genital warts and advanced cervical lesions, data on the vaccine's ability to prevent cervical cancer were lacking until this newly published study.
The study's lead researcher states that the results proved that vaccination significantly reduces the risk of invasive cervical cancer, the main purpose of the vaccination program, providing strong evidence for cancer prevention. Another team member summarizes the results in these words: "We found that the study results show that the quadrivalent HPV vaccine protects against sexually transmitted HPV infection and that this reduces cervical cancer risk in young women up to the age of 30. This is a very important development in cancer prevention. However, we still observed that women vaccinated against HPV could develop cervical cancer, though at a slower rate. Therefore, vaccination at an early age and continued screening later in life are extremely important in preventing cervical cancer."
Details of the study on cervical cancer prevention with the HPV vaccine
The study included women who had and had not received the quadrivalent HPV vaccine and compared their rates of cervical cancer diagnosis. Accordingly, among vaccinated women, out of 100,000, 47 were diagnosed with cervical cancer, whereas among unvaccinated women, out of 100,000, this number rose to 94.
The importance of age at vaccination
The age at vaccination is also extremely important, the researchers said. To demonstrate this, they compared 100,000 women vaccinated before age 17 with women vaccinated between ages 17 and 30. According to the results, among women vaccinated at an early age, out of 100,000 vaccinated women, 4 were diagnosed with cervical cancer, while when vaccination was given at an older age, this number rose to 54.
Following these results, the researchers commented on the data in these words: "Compared with women who had never received an HPV vaccine, women vaccinated before age 17 had an 88% lower risk. For this reason, early quadrivalent HPV vaccination for women, before exposure to HPV infection, is what we strongly recommend."
While emphasizing the importance of vaccination in preventing cervical cancer, the researchers also stress that lifestyle is extremely important. Being overweight, tobacco use, and sexual life are also among cervical cancer risk factors, showing that protection with the HPV vaccine alone is not enough and that we also need to change our lifestyle.
Summary and conclusion
Research has shown that HPV is also associated with cancers of the head and neck, vagina and vulva, anus, rectum and penis. Although cancers other than cervical cancer take longer to develop, the HPV vaccine also provides protection against these cancers.

The HPV vaccine offers an extremely easy and effective method of cancer prevention. The recommended ideal vaccination age for both females and males is 11-12. Receiving the HPV vaccine at the recommended ages and changing lifestyle are highly effective ways to help protect against many cancers, particularly cervical cancer.

RELATED TOPICS
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.